Finance

Sanofi to acquire Vigil Neuroscience in $470 million deal

Published by Global Banking & Finance Review

Posted on May 22, 2025

1 min read

· Last updated: January 23, 2026

Add as preferred source on Google
Sanofi to acquire Vigil Neuroscience in $470 million deal
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) -Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million. (Reporting by Bipasha

Sanofi Agrees to $470 Million Acquisition of Vigil Neuroscience

(Reuters) -Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.

(Reporting by Bipasha Dey in Bengaluru; Editing by Mohammed Safi Shamsi)

Key Takeaways

  • Sanofi to acquire Vigil Neuroscience for $470 million.
  • The deal values Vigil at $8 per share in cash.
  • Vigil Neuroscience is a clinical-stage biotech company.
  • Sanofi aims to expand its biotech portfolio with this acquisition.
  • The acquisition was reported by Reuters.

Frequently Asked Questions

What is the acquisition price per share for Vigil Neuroscience?
Sanofi will acquire Vigil Neuroscience for $8 per share in cash.
What is the total value of the deal?
The acquisition is valued at approximately $470 million.
Who reported the acquisition news?
The news was reported by Bipasha Dey in Bengaluru.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category